This forum post is hidden because you have chosen to ignore GailL1. Show Details
This forum post is hidden because you have submitted an abuse report against it. Show Details
Here are the last results of the 2nd year of trials.
"Avastin and Lucentis block growth of abnormal blood vessels and leakage of fluid from the vessels. Lucentis was approved by the U.S. Food and Drug Administration (FDA) in 2006 for the treatment of AMD. Avastin is very similar to Lucentis but is not approved by the FDA for this purpose. Avastin is approved for other indications. Most clinicians use these drugs on an as-needed basis when there is evidence of active disease, such as fluid leakage.
The results plainly state that even though Lucentis was the 1st Rx approved by the FDA for treatment that as of this date, Avastin is most frequently used to treat AMD and as of this date it is used "off-label" because the FDA hadn't approve it for this use.
I even checked Avastin on the FDA website - no mention of this use on the criteria. So it is still off-label use and perhaps this answers the question of the thread -